Overview

Propranolol for Sleep Apnea Therapy

Status:
Enrolling by invitation

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The primary objective in this study is to test whether propranolol lowers glucose and free fatty acid levels during sleep in obstructive sleep apnea (OSA), and preserves vascular function (EndoPAT) versus placebo. The secondary objective is to test whether propranolol influences sleep quality, architecture, and hemodynamics in OSA. OSA will be elicited by temporarily discontinuing CPAP therapy in patients with a history OSA accustomed to CPAP therapy (CPAP withdrawal).

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Propranolol